These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 8555790

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK.
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Future therapies for Parkinson's disease.
    Hauser RA, Lyons KE.
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May 22; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract] [Full Text] [Related]

  • 9. Monoamine oxidase inhibitors--is it time to up the TEMPO?
    Rascol O.
    Lancet Neurol; 2003 Mar 22; 2(3):142-3. PubMed ID: 12849233
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Selegiline's neuroprotective capacity revisited.
    Riederer P, Lachenmayer L.
    J Neural Transm (Vienna); 2003 Nov 22; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract] [Full Text] [Related]

  • 12. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW, Mytilineou C, Tatton W.
    Mov Disord; 1998 Nov 22; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N.
    Am J Geriatr Pharmacother; 2007 Jun 22; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS, Fazzini E, Volkow ND.
    Ann Neurol; 1996 Aug 22; 40(2):267-8. PubMed ID: 8773616
    [No Abstract] [Full Text] [Related]

  • 18. Deprenyl in Parkinson's disease.
    Korczyn AD, Nisipeanu P.
    Ann Neurol; 1996 Aug 22; 40(2):268-9. PubMed ID: 8773617
    [No Abstract] [Full Text] [Related]

  • 19. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C, Schumacher HC, Burgut FT.
    Expert Rev Neurother; 2005 Nov 22; 5(6):811-21. PubMed ID: 16274338
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Parkinson's disease.
    Eadie MJ.
    Aust Fam Physician; 1995 Sep 22; 24(9):1685-7, 1690-2. PubMed ID: 7487655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.